MUC1 and neoplasm: Li and coworkers used vaccines containing full-length MUC1 VNTR epitopes glycosylated variably at a Ser and/or Thr residue within the VNTR (HGVTSAPDT*RPAPGS*TAPPA) to induce IgG antibodies capable of recognizing tumor cells (Cai et al., 2014).